FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1483-1484 October 9, 2003 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Reliable assessment of molecular remission after allografting for chronic myeloid leukemia requires assays capable of detecting one BCR-ABL–positive cell among 10⁵ to 10⁶ BCR-ABL–negative cells¹ — a sensitivity achieved with nested reverse-transcriptase polymerase chain reaction (PCR) but not with real-time quantitative PCR.² Molecular remission after allografting predicts a low risk of relapse.¹ On the basis of negative results on quantitative PCR testing, molecular remission has also been reported in some patients treated with imatinib.^3,4

The sensitivity of any PCR assay is ultimately limited by the number of cells analyzed. Only a fraction of the complementary . . . [Full Text of this Article]

This article has been cited by other articles:

• Deininger, M. W. (2008). Nilotinib. Clin. Cancer Res. 14: 4027-4031 [Full Text]  
• Deininger, M., Buchdunger, E., Druker, B. J. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653 [Abstract] [Full Text]